News | Cardiovascular Clinical Studies | November 06, 2023

Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023

New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS (mavacamten) for patients with symptomatic obstructive HCM 

New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS (mavacamten) for patients with symptomatic obstructive HCM

November 6, 2023 —  Bristol Myers Squibb  announced that research across the company’s cardiovascular franchise will be presented at the American Heart Association’s (AHA) annual Scientific Sessions, taking place November 11-13, 2023 in Philadelphia, Pennsylvania. Clinical trial data to be featured include new analyses of the effectiveness of CAMZYOS (mavacamten) in patients with and without gene variants from the Phase 3 EXPLORER-HCM study, as well as new real-world analyses of patients with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) receiving CAMZYOS in clinical practice. 

The Bristol Myers Squibb-Pfizer Alliance will also provide new data describing disparity in oral anticoagulant utilization patterns among commercially insured patients with non-valvular atrial fibrillation (NVAF) with high stroke risk by geographic region and race in the U.S.

“We’re looking forward to the opportunity to showcase new clinical and real-world analyses across our cardiovascular franchise, which support our commitment to develop medicines that address the global burden of cardiovascular disease,” said Roland Chen, Senior Vice President, Head of Development, Immunology, Cardiovascular & Neurology. “These data at the AHA Scientific Sessions continue to demonstrate the benefit that treatment with CAMZYOS provides for a broad spectrum of patients with symptomatic obstructive hypertrophic cardiomyopathy in clinical studies as well as in clinical practice.”  

  

Key presentations include: 

  • An exploratory subgroup analysis of the Phase 3 EXPLORER-HCM study analyzing treatment effectiveness with CAMZYOS for patients with and without sarcomere gene variants. 
  • Findings from an analysis of an EXPLORER-HCM study assessing the relationship between patient-reported KCCQ and physician-assessed NYHA class to enhance understanding of KCCQ scores and aid shared decision-making process of patients and physicians in clinical practice. 
  • A retrospective cohort study of claims data from commercial specialty pharmacies demonstrating high real-world adherence to CAMZYOS in >600 patients with symptomatic obstructive HCM in the United States. 
  • An analysis of Medicare claims data from 2016 to 2020 investigating evidence of diagnosis-related disparities in patients over 65 with HCM specifically relating to race/ethnicity and county-level disparities. 

  

Summary of Presentations

Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at AHA Congress 2023 include: 

  

Abstract Title 

Primary Author 

Type/# 

Session Title 

Time (EST) 

Saturday, November 11, 2023 

Real-World Adherence to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in the United States 

Masri, A. 

Poster – 3002 

Drugs, Drugs, and More Drugs: New Pharmacologic Insights in Heart Failure Management 

11:30 AM –12:45 PM 

  

Disparities in Speed of Diagnosis of Hypertrophic Cardiomyopathy in the United States 

Masri, A. 

Rapid Oral Fire – 515 

Exciting Developments in Heart Failure Diagnosis and Evaluation 

12:10 PM –12:15 PM 

  

Healthcare Resource Utilization and Costs Associated With New York Heart Association Functional Class in Patients With Obstructive Hypertrophic Cardiomyopathy in the United States 

Wang, Y. 

Poster – 3116 

Socioeconomic Disparities and Cardiovascular Health 

3:00 PM –4:15 PM 

  

Biomarker Profile of Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction or Reduced Ejection Fraction: Insights From the ARISTOTLE Trial* 

Pol, T. 

Poster - 1059 

HFpEF 

3:00 PM – 4:15 PM 

Sunday, November 12, 2023 

Real-World Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: A US Single Center Experience 

Reza, N. 

Poster – 2160 

Hypertrophic, Obstructive, and Takotsubo Cardiomyopathy: From Genetics to Outcomes 

11:30 AM –12:45 PM 

  

Monday, November 13, 2023        

Relationship Between the Kansas City Cardiomyopathy Questionnaire Score and New York Heart Association Class in Patients With Hypertrophic Cardiomyopathy: Insights from EXPLORER-HCM 

Sherrod, C. 

Poster - 2194 

Game Changing Disease Management in Hypertrophic, Amyloid, and Cardiomyopathy Care 

10:30 AM –11:45 AM 

  

Geographic and Racial Variation in Oral Anticoagulant Treatment Among Commercially Insured Patients With Non-Valvular Atrial Fibrillation in the United States* 

Atwater, B. 

E-poster - 2146 

Treatment of Arrhythmias: Risk Stratification for Stroke and Stroke Reduction Therapies 

  

1:30 PM –2:45 PM 

  

Response to Mavacamten by Sarcomere Gene Mutation Status in EXPLORER-HCM 

Ho, C. 

Rapid fire oral – 551 

  

The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms 

1:50 PM –1:55 PM 

  

The Effect of Mavacamten Treatment on Hemolysis Biomarkers in Patients With Obstructive Hypertrophic Cardiomyopathy in the EXPLORER-HCM Study 

Wang, Z. 

Rapid fire oral – 553 

The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms 

2:10 PM –2:15 PM 

  

 

For more information: https://www.bms.com/ 

Find more AHA23 conference coverage here


Related Content

News | AHA

July 9, 2024 — The American Heart Association, celebrating 100 years of lifesaving service as the world’s leading ...

Home July 09, 2024
Home
News | AHA

June 18, 2024 — At least 6 in 10 adults in an older, more diverse U.S. population could be affected by cardiovascular ...

Home June 18, 2024
Home
News | AHA

May 24, 2024 — The American Heart Association has issued a statement warning that false information about COVID ...

Home May 24, 2024
Home
News | AHA

February 9, 2024 — Injection of a substance to block an artery feeding the dura (protective sack around the brain) — ...

Home February 09, 2024
Home
News | AHA

February 8, 2024 — The American Heart Association (AHA), currently celebrating its centennial year, announced that it is ...

Home February 08, 2024
Home
News | AHA

February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association’s ...

Home February 08, 2024
Home
News | AHA

February 7, 2024 — According to results from a multi-center trial in the United States, called Zero Degree Head ...

Home February 07, 2024
Home
News | AHA

February 7, 2024 — Researchers presenting preliminary late-breaking science presented on the first day of the American ...

Home February 07, 2024
Home
News | AHA

February 7, 2024 — Eleven scientists leading the way in stroke research will be recognized during the American Stroke ...

Home February 07, 2024
Home
News | AHA

January 23, 2024 — Focused on delivering the latest scientific advancements and new treatments in cerebrovascular ...

Home January 22, 2024
Home
Subscribe Now